Sep 9, 2026, 00:20 UTC
On the fifth and final day of the 2026 national medical insurance drug list negotiations, price consultations for the commercial insurance innovative drug catalog began, with multiple pharmaceutical companies including AstraZeneca, Sanofi, and subsidiaries of Kechi Life and Hengrundasheng entering the venue.
Sep 7, 2026, 16:30 UTC
Pharmaceutical company Sanofi announced an investment of nearly $300 million in a Toronto AI Center of Excellence.
Source:Aug 17, 2026, 19:23 UTC
Sanofi will lay off 229 workers in Massachusetts, affecting employees of Blueprint Medicines, which Sanofi acquired in a $9.1 billion deal in July 2025.
Source:Aug 9, 2026, 23:16 UTC
Sanofi alerted patient groups and physicians in the U.S. and Europe that supplies of Myozyme and Nexviazyme are dwindling due to a bottleneck in the final manufacturing phase and quality control issues at its Waterford plant.
Source:Aug 4, 2026, 11:00 UTC
Nurix Therapeutics earned a $10 million milestone payment after collaborator Sanofi initiated a Phase 1 clinical trial of the oral STAT6 degrader SAR448272/NX-3911 for type 2 inflammatory diseases.
Source:Aug 4, 2026, 05:00 UTC
The European Commission approved Sanofi's MenQuadfi vaccine for use in infants from six weeks of age against invasive meningococcal disease.
Source:Jul 30, 2026, 17:06 UTC
Sanofi reported Q2 2026 earnings and sales that beat expectations, with Dupixent quarterly sales exceeding 5 billion euros for the first time.
Source:Jul 24, 2026, 16:15 UTC
The African Development Bank finalized a loan of up to $15 million to Biovac to support a new multi-vaccine manufacturing facility in Cape Town.
Jul 24, 2026, 11:53 UTC
Japan's parliament passed a revised Vaccination Act that treats antibody preparations as equivalent to vaccines, enabling public funding for RS virus preventive treatment.
Source:Jul 24, 2026, 05:30 UTC
Sanofi announced discontinuation of clinical development of amlitelimab in moderate-to-severe atopic dermatitis.
Jul 23, 2026, 16:23 UTC
Sanofi's Lantus Solostar insulin pen is experiencing supply shortages due to increased demand, and the company is accelerating production to address the issue.
Source:Jul 21, 2026, 16:00 UTC
Sanofi announced an evolution of its Executive Committee to support its next strategic chapter.
Source:Jul 21, 2026, 11:03 UTC
Sanofi's Japanese subsidiary announced a delay in the launch of its high-dose influenza vaccine 'Efluelda' for older adults, originally planned for autumn 2026.
Source:Jul 17, 2026, 10:30 UTC
Aqemia and Sanofi expanded their research collaboration, nominating a new therapeutic target and making an additional payment.
Source:Jul 13, 2026, 20:01 UTC
Paulo Fontoura resigned from the Board of Directors of Lakefront Biotherapeutics NV after being appointed Global Head of R&D at Sanofi SA.
Jul 10, 2026, 12:35 UTC
The US FDA approved Sanofi's subcutaneous Sarclisa Escena as the first anticancer treatment administered via an on-body injector.
Source:Jul 8, 2026, 10:00 UTC
The European Commission seeks feedback on commitments offered by Sanofi to address suspected anti-competitive behaviour in a flu vaccine marketing campaign.
Source:Jul 2, 2026, 10:46 UTC
Sanofi inaugurated its first China Innovation and Operations Center in Chengdu, which was officially established in March 2026.
Source:Jun 30, 2026, 05:44 UTC
Sanofi's Nexviazyme drug met primary and secondary goals in a late-stage clinical trial for the most aggressive variant of Pompe disease in infants.
Source:Jun 26, 2026, 10:47 UTC
The European Commission launched an antitrust probe into French drugmaker Sanofi over alleged misleading communications against rival flu vaccine Fluad.
Jun 23, 2026, 05:15 UTC
Japan's Ministry of Health, Labour and Welfare granted marketing and manufacturing authorization to Sanofi's Wayrilz for the treatment of immune thrombocytopenia.
Source:Jun 22, 2026, 14:22 UTC
Bionyra Pharma launched and raised €143 million in an oversubscribed Series A financing round co-led by Jeito Capital and Sofinnova Partners, with participation from Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Health Ventures.
Source:Jun 19, 2026, 10:31 UTC
Japan's Ministry of Health, Labour and Welfare approved Sanofi's Sarclisa subcutaneous formulation for multiple myeloma.
Source:Jun 18, 2026, 12:00 UTC
COUR Pharma closed a $50 million Series B financing round led by Lumira Ventures and Roche Venture Fund with new investment from Sanofi.
Source:Jun 15, 2026, 17:15 UTC
Sanofi received FDA approval to expand the use of Tzield in children with newly diagnosed stage 3 type 1 diabetes.
Source:Jun 13, 2026, 13:22 UTC
The FDA approved teplizumab, a type 1 diabetes drug developed by Sanofi, for children aged 8 and older with stage 3 diabetes.
Source:Jun 12, 2026, 22:09 UTC
Sanofi's Tzield received US approval as the first disease-modifying therapy for recently diagnosed stage 3 type 1 diabetes patients.
Source:Jun 8, 2026, 17:41 UTC
Sanofi received European Union approval for a subcutaneous formulation of Sarclisa for the treatment of multiple myeloma.
Source:
Page 1Next →